Thomas Schluep
- Hepatology top 1%
- Hepatitis C virus research 8
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery 9
- Epidemiology top 5%
- Hepatitis B Virus Studies 17
- Liver Disease Diagnosis and Treatment 6
- Pharmaceutical Science top 2%
- Molecular Biology top 10%
- RNA Interference and Gene Delivery 16
- Cancer therapeutics and mechanisms 8
-
- Virus-based gene therapy research 6
-
- Viral gastroenteritis research and epidemiology 5
- Co-authors
- Mark E. DavisJungyeon HwangBruce D. GivenChing‐Lung LaiRobert G. GishStephen LocarniniJeremy D. HeidelJohnson Y.N. Lau
- Cited by
- HepatologyBiomaterialsEpidemiology
- Journals
- New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (2 papers)Nucleic Acids Research (1 paper)
- Partner nations
- United StatesHong KongAustralia
In The Last Decade
Thomas Schluep
47 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 94
- Hepatology 690
- Biomaterials 645
- Epidemiology 873
- Pharmaceutical Science 137
- Molecular Biology 1.2k
Countries citing papers authored by Thomas Schluep
This map shows the geographic impact of Thomas Schluep's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Schluep with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Schluep more than expected).
Fields of papers citing papers by Thomas Schluep
This network shows the impact of papers produced by Thomas Schluep. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Schluep. The network helps show where Thomas Schluep may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Schluep, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 12 | |
| 2 | 2024 | 17 | |
| 3 | 2022 | 65 | |
| 4 | 2022 | 13 | |
| 5 | 2021 | 37 | |
| 6 | First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA) | 2019 | 7 |
| 7 | 2017 | 342 | |
| 8 | Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520 | 2016 | 1 |
| 9 | 2016 | 3 | |
| 10 | 2015 | 113 | |
| 11 | 2015 | 188 | |
| 12 | 2011 | 78 | |
| 13 | 2009 | 81 | |
| 14 | 2008 | 49 | |
| 15 | 2005 | 118 | |
| 16 | 2005 | 13 | |
| 17 | 2003 | 10 | |
| 18 | 1998 | 68 | |
| 19 | 1998 | 9 | |
| 20 | 1998 | 151 |
About Thomas Schluep
Thomas Schluep is a scholar working on Hepatology, Biomaterials and Epidemiology, having authored 47 papers that have together received 2.6k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (17 papers), RNA Interference and Gene Delivery (16 papers), Nanoparticle-Based Drug Delivery (9 papers), Cancer therapeutics and mechanisms (8 papers), Hepatitis C virus research (8 papers), Virus-based gene therapy research (6 papers), Liver Disease Diagnosis and Treatment (6 papers) and Viral gastroenteritis research and epidemiology (5 papers). The work is most often cited by research in Hepatology (690 citations), Biomaterials (645 citations) and Epidemiology (873 citations). Thomas Schluep has collaborated with scholars based in United States, Hong Kong and Australia. Frequent co-authors include Mark E. Davis, Jungyeon Hwang, Bruce D. Given, Ching‐Lung Lai, Robert G. Gish, Stephen Locarnini, Jeremy D. Heidel, Johnson Y.N. Lau, David L. Lewis and Jianjun Cheng. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.